Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel.
Jo CaersB PaivaE ZamagniX LeleuJ BladéS Y KristinssonC TouzeauN AbildgaardE TerposR HeusschenE OcioM DelforgeO SezerM BeksacH LudwigG MerliniP MoreauS ZweegmanM EngelhardtL RosiñolPublished in: Journal of hematology & oncology (2018)
Solitary plasmacytoma is an infrequent form of plasma cell dyscrasia that presents as a single mass of monoclonal plasma cells, located either extramedullary or intraosseous. In some patients, a bone marrow aspiration can detect a low monoclonal plasma cell infiltration which indicates a high risk of early progression to an overt myeloma disease. Before treatment initiation, whole body positron emission tomography-computed tomography or magnetic resonance imaging should be performed to exclude the presence of additional malignant lesions. For decades, treatment has been based on high-dose radiation, but studies exploring the potential benefit of systemic therapies for high-risk patients are urgently needed. In this review, a panel of expert European hematologists updates the recommendations on the diagnosis and management of patients with solitary plasmacytoma.
Keyphrases
- single cell
- computed tomography
- positron emission tomography
- magnetic resonance imaging
- end stage renal disease
- high dose
- bone marrow
- newly diagnosed
- ejection fraction
- chronic kidney disease
- mesenchymal stem cells
- peritoneal dialysis
- multiple myeloma
- radiation therapy
- induced apoptosis
- low dose
- stem cells
- patient reported outcomes
- signaling pathway
- pet imaging
- magnetic resonance
- image quality
- contrast enhanced
- cell therapy
- ultrasound guided
- endoplasmic reticulum stress
- radiation induced